Povl Krogsgaard-Larsen

Graduated from The Royal Danish School of Pharmacy: 1967.
Lic.pharm. (Ph.D.) from The Royal Danish School of Pharmacy: 1970.
Dr.pharm. (D.Sc.) from The Royal Danish School of Pharmacy: November 1980.

Lektor (associate professor) at The Royal Danish School of Pharmacy 1970.
Professor (Medicinal chemistry) at The Royal Danish School of Pharmacy 1986.
F. Merz-Stiftungsgastprofessor, Goethe University, Frankfurt: March–December 1992
Doctor Honoris Causa, Louis Pasteur University, Strasbourg, France: December 1992.
Doctor Honoris Causa, Uppsala University, Sweden: January 2000.
Doctor Honoris Causa, Milano University, Italy: January 2008.

Member of The Royal Danish Academy of Sciences and Letters 1986–.
Member of The Danish Academy of Natural Sciences 1987–.
Member of The Danish Academy of Technical Sciences 1987–.
Member of The Danish Medical Research Council 1988–1994.
Trustee of The Alfred Benzon Foundation 1991–.
Member of the board of directors of the Carlsberg Foundation 1993–.
Chairman of the board of directors of the Carlsberg Foundation 2003–.
Member of the board of directors of Carlsberg A/S 1993–.
Chairman of the board of directors of Carlsberg A/S 2003–.
Member of the board of directors of the Carlsberg Laboratory 1993–.
Chairman of the board of directors of the Carlsberg Laboratory 1996–2002.
Member of the board of directors of Auriga A/S 2002–.
European Editor for Journal of Medicinal Chemistry 1998–. 

Academic Leadership
Chairman of The Biotechnological Drug Research Center, PharmaBiotec, 1987–1999.
Director of NeuroScience PharmaBiotec - A Strategic Drug Research Centre, 1997–2001.
Director of Graduate School of Drug Research, 1998–2002.
Chairman of the board of Drug Research Academy, 2002–.
Coordinator of Neuro-Medicinal Chemistry. Molecular Design, Specificity and Recognition (The Lundbeck Foundation), 1994–1998 and 1999–2001.
Rector at The Royal Danish School of Pharmacy 2001–2002.

Recipient of The H. C. Ørsted Award, June 1967.
Recipient of The Hede Nielsen Research Award, June 1981.
Recipient of The Ole Rømer Research Award, September 1983.
Recipient of The Danish Pharmaceutical Society Research Award, October 1987.
Recipient of The Lundbeck Foundation Prize, Copenhagen, December 1989.
Recipient of The Paul Ehrlich Prize, Grenoble, France, July 1989.
Recipient of The Astra Award, September 1991.
Recipient of The W. Th. Nauta Award, Maastricht, The Netherlands, September 1996.
Recipient of The Danish Academy of Natural Sciences Industrial Research Award, Copenhagen, Denmark, November 1996.
Recipient of The Grindel Award, Riga, Latvia, October 1998.
Recipient of The Pharmaceutical Research Achievement Award, Kyoto, Japan, May 2004.
Recipient of The H.C. Ørsted Gold Medal, December 2006.

In 1970/71 Povl Krogsgaard-Larsen (PKL) established a research group in medicinal chemistry, which developed a drug design project in the GABA neurotransmitter field.

In 1975 this group designed the first specific GABA uptake inhibitor, nipecotic acid, and subsequently a series of such compounds. During the period 1976-1979 PKL and his group, succeeded in the design of the first specific GABA_A receptor agonist, isoguvacine, and a number of related specific GABA_A agonist.

THIP, a heterocyclic bioisostere of isoguvacine, was designed by PKL and optimized pharmacokinetically for clinical studies.

In 1972, PKL established research projects in the field of excitatory amino acid (EAA) neurotransmitters. Using the Amanita muscaria constituent, ibotenic acid, as a lead structure, a number of specific EAA receptor agonists have been designed and introduced in the international EAA research field. AMPA is a notable example, and this compound has given name to the AMPA subtype of EAA receptors. This group has succeeded in converting the agonist AMPA into the EAA antagonist AMOA and AMPA-related ligands capable of enhancing EAA receptor functions without activating the receptors directly.

In 1985-1986 PKL and his group designed novel ester bioisosteres in the acetylcholine receptor field. Using this principle, a number of very potent subtype-selective muscarinic and nicotinic receptor agonists and partial agonists were designed.

2 Theses: Ph.D. (1970), D.Sc. (1980)
8 Books (editor)
Textbook of Medicinal Chemistry, 1st edition 1991; 2nd edition 1996; 3rd edition 2002.
11 International Symposia (organizer or co-organizer)
Invited Speaker at 125 international symposia and congresses

433 original and review articles:

1969-1980 70 articles,
1981-1990 144 articles,
1991-1995 75 articles,
1996-2000 76 articles,
2001-2007 68 articles